- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Glycosylation Improves the Proteolytic Stability of Exenatide
-
- Chaitra Chandrashekar
- The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria 3052, Australia
-
- Yuji Nishiuchi
- GlyTech, Inc., 134 Chudoji Minamimachi, Kyoto 600-8813, Japan
-
- Barbara Fam White
- Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria 3084, Australia
-
- Yanni Arsenakis
- Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria 3084, Australia
-
- Feng Lin
- The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria 3052, Australia
-
- Samantha M. McNeill
- Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
-
- Peishen Zhao
- Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
-
- Sam van Dun
- EnzyTag B.V., Daelderweg 9, 6361HK Nuth, The Netherlands
-
- Anna Koijen
- EnzyTag B.V., Daelderweg 9, 6361HK Nuth, The Netherlands
-
- Yasuhiro Kajihara
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043 Japan
-
- Denise Wootten
- Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
-
- Leendert J. van den Bos
- EnzyTag B.V., Daelderweg 9, 6361HK Nuth, The Netherlands
-
- John D. Wade
- The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria 3052, Australia
-
- Mohammed Akhter Hossain
- The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria 3052, Australia
Search this article
Description
Exenatide was the first marketed GLP-1 receptor agonist for the treatment of type 2 diabetes. Modification to the chemical structure or the formulation has the potential to increase the stability of exenatide. We introduced human complex-type sialyloligosaccharide to exenatide at the native Asn28 position. The synthesis was achieved using both solid phase peptide synthesis (SPPS) and Omniligase-1-mediated chemoenzymatic ligation. The results demonstrate that glycosylation increases the proteolytic stability of exenatide while retaining its full biological activity.
Journal
-
- Bioconjugate Chemistry
-
Bioconjugate Chemistry 34 (6), 1014-1018, 2023-05-16
American Chemical Society (ACS)